Compass Therapeutics (NASDAQ:CMPX) is a clinical‐stage biopharmaceutical company focused on discovering and developing precision immunotherapies to treat cancer and immune‐mediated diseases. The company leverages proprietary antibody engineering and molecular design platforms to generate novel therapeutic candidates with the goal of improving efficacy and safety over existing treatments. Compass’s research efforts target pathways involved in tumor immune evasion as well as chronic inflammatory and fibrotic processes, with a particular emphasis on next‐generation antibody modalities and Fc engineering to optimize immune system engagement.
The company’s pipeline includes multiple antibody candidates in preclinical and early clinical development. Its lead programs are designed to modulate key immune checkpoints and costimulatory receptors, while additional assets address tissue fibrosis and other immune dysregulation disorders. Compass works in collaboration with academic institutions and industry partners to advance its drug candidates through Phase 1 and Phase 2 studies, aiming to deliver first‐in‐class or best‐in‐class therapies for patient populations with high unmet medical needs.
Founded in 2018 as a spin‐out from leading immunology research groups, Compass Therapeutics is headquartered in Cambridge, Massachusetts, in the heart of the Boston biotech cluster. Since its inception, the company has grown its scientific team to include experts in antibody discovery, immuno‐engineering, process development, and clinical operations. Its state‐of‐the‐art laboratory facilities support advanced screening, lead optimization, and translational immunology research.
Compass serves a global patient community by conducting multi‐regional clinical trials across North America, Europe and Asia, and by engaging key opinion leaders in oncology and immunology. The company’s leadership team is composed of seasoned industry veterans with backgrounds at major biopharmaceutical firms and research institutions. This experienced management group oversees strategic alliances, regulatory interactions, and the execution of a development roadmap aimed at bringing innovative immunotherapies to market.
